CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

Published:2004-02 Issue:2 Volume:34 Page:336-344
ISSN:0014-2980
Container-title:European Journal of Immunology
language:en
Short-container-title:Eur. J. Immunol.

Author:

Ghiringhelli François,Larmonier Nicolas,Schmitt Elise,Parcellier Arnaud,Cathelin Dominique,Garrido Carmen,Chauffert Bruno,Solary Eric,Bonnotte Bernard,Martin François

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Cited by 793 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities”;Cancer Letters;2024-08

2. Nanoparticle-mediated metronomic chemotherapy in cancer: A paradigm of precision and persistence;Cancer Letters;2024-07

3. Combined oral low-dose cyclophosphamide endocrine therapy may improve clinical response among patients with metastatic breast cancer via Tregs in TLSs;Scientific Reports;2024-06-11

4. T-Cell Engagers—The Structure and Functional Principle and Application in Hematological Malignancies;Cancers;2024-04-20

5. New approaches and prospects of immunotherapy and gene therapy for prostate cancer;Journal of Translational Genetics and Genomics;2024-03-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP